yes part of the issue was biosimilars cutting into roche products.. from reading halo investor presentation, enhaze could allow reformulation w new patent protection... so short term blip imo and not fully researched... what is gaining traction is the delivery mode of enhaze which makes treatment a lot faster and more efficient vs IV delivery...
News 
Market Data 
Discover 
